Latest filing published 26 Aug 2026 for AtriCure, Inc., €392k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Karl S. Dahlquist on record concern AtriCure, Inc., in the capacity of senior executive. We count 29 filings; the first trade dates from 30 June 2021 and the latest from 24 August 2026.
No open-market purchase appears, only 8 sales worth €1.2M. Other entries cover 21 share grants. 2026 to date brings no purchases and 1 sale.
On 26 August 2026 came the latest disclosure, an open-market sale for €392k in AtriCure, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations